PRecision gerOMedicinE: Tailored Healthy agEing With Lifestyle, sUpplements and drugS (PROMETHEUS)
National University of Singapore
20 participants
Sep 29, 2025
INTERVENTIONAL
Summary
As the population ages, the growing prevalence of age-related diseases is creating substantial challenges for healthcare systems worldwide. Current therapeutic strategies often target individual diseases and decrease mortality without improving healthspan. The geroscience hypothesis suggests that targeting the ageing process itself could prevent, delay, or manage the severity of multiple age-related diseases concurrently, thereby improving overall healthspan and reducing healthcare burdens. Emerging research highlights several interconnected hallmarks of aging, such as mitochondrial dysfunction, chronic inflammation, impaired autophagy, and immune dysregulation, as modifiable through targeted interventions. Precision geromedicine represents a paradigm shift in addressing these processes, combining baseline diagnostics with individualized treatment strategies that adapt over time based on patient response. This approach integrates lifestyle modifications, dietary supplements, and pharmacological agents to optimize physical, cognitive, and immune function across the lifespan .
Eligibility
Inclusion Criteria10
- Age 50-80 years (both male and female)
- Relatively healthy and in stable health condition
- Not engaged in regular resistance or aerobic training in the past 12 months (i.e., untrained)
- VO₂peak below the 75th percentile for age- and sex-specific norms
- Cognitive performance below 75th percentile on the NIH Toolbox Cognitive Function Battery
- Willing and able to comply with exercise and supplementation protocols
- English-literate (can read and understand English)
- Provides written informed consent
- Deemed to have mental capacity, as assessed by the Principal Investigator
- Are able to attend all research visits for screening and research data collection at MD11, Yong Loo Lin School of Medicine, National University of Singapore
Exclusion Criteria9
- Significant change in medication in the past 3 months
- History of major cardiovascular disease (e.g., coronary artery disease, heart failure, stroke)
- More than two unstable chronic conditions (e.g., hypertension, diabetes, osteoarthritis, COPD)
- Known allergies to soy, shellfish/seaweed, mushrooms, or supplement ingredients
- Participation in another interventional clinical trial
- Current use of any study-related supplement unless willing to stop
- Any medical, psychiatric, or cognitive condition deemed by the PI to jeopardise safety or compliance
- Pregnant or planning pregnancy during the study period
- Any conditions deemed by PI that jeopardize the safety or study compliance
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Sleep hygiene education and individualized dietary recommendations delivered throughout the intervention period.
Supervised dual-task cognitive-physical training with an exergaming component conducted three times per week, 60 minutes per session.
Structured motivational interviewing sessions aimed at improving adherence to lifestyle and supplementation interventions conducted two times throughout the study.
Daily whey protein supplementation (GOLD STANDARD 100% ISOLATE, Optimum Nutrition) provided using a standard 30 g scoop (\~25 g protein). Dosage based on body weight: 40-59 kg: 1 scoop/day 60-89 kg: 1.5 scoops/day ≥90 kg: 2 scoops/day
Daily creatine supplementation (Micronized Creatine Monohydrate, Optimum Nutrition; 1.25 g per capsule). Dosage based on body weight: 40-59 kg: 4 capsules/day 60-89 kg: 6 capsules/day ≥90 kg: 8 capsules/day
Daily fucoidan supplementation (SIRT6Activator®, DoNotAge.org) at a dose of 2.4 g/day.
Participants below the 50th percentile for normative muscle mass receive urolithin A (StanYouth™ Urolithin A, Bonerge) at 250 mg/day.
Participants below the 50th percentile for normative VO₂peak receive NMN (AbinoNutra® NMN, Abinopharm, Inc.) at 300 mg/day.
Participants below the 50th percentile for normative cognitive performance receive a gender-specific multivitamin (Centrum), 1 tablet daily.
At the midpoint of the intervention (1 month), participants may receive ergothioneine (Dr.Ergo® L-ergothioneine) at 25 mg three times per week based on individual response.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07451496